Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Prevalence and Risk Factors of Dengue Virus Infection Among Febrile Patients in a Malaria Hyperendemic Area of Southern Mali.

Research square·2026

Same author

Evaluating vectors for the design of a spillover-disrupting Lassa virus transmissible vaccine.

PLoS computational biology·2026

Same author

Highly efficient anogenital transmission of clade Ia monkeypox virus associated with increased shedding.

Nature communications·2026

Same author

Hantavirus seroprevalence and associated factors for exposure in south-central Uganda.

Emerging microbes & infections·2026

Same author

Griffithsin-mediated inhibition of cellular entry of hemorrhagic fever viruses and insights into its mechanisms.

Journal of virology·2026

Same author

A replicating RNA vaccine protects cynomolgus macaques against lethal clade 2.3.4.4b influenza A H5N1 virus challenge.

Science translational medicine·2025

Same journal

Correction: Peptine et al. Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) and Vancomycin-Resistant Enterococci (VRE) in Nosocomial Infections: A Systematic Review of Resistance, Pathogenesis, and Clinical Management. <i>Microorganisms</i> 2026, <i>14</i>, 428.

Microorganisms·2026

Same journal

Torque Teno Virus (TTV) Plasma Load and Immune Reconstitution in People Living with HIV: A Systematic Review.

Microorganisms·2026

Same journal

Optimizing Bacteriophage Screening and Isolation Methods for Microbial Samples Derived from Different Body Sites of Cattle.

Microorganisms·2026

Same journal

Enhanced Biphenyl Degradation by <i>Rhodococcus</i> sp. TG-1 Under Cr(VI) Stress via Modified Biochar Immobilization.

Microorganisms·2026

Same journal

In Vitro Detection of Biologically Active Staphylococcal Enterotoxins Type B and C1 as an Alternative to In Vivo Testing.

Microorganisms·2026

Same journal

Monitoring Hygiene Protocols and Exploring Alternatives to Counteract Resistant Pathogens: A Case Study from Southern Italy on Healthcare-Associated Infection Control.

Microorganisms·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Nov 7, 2025

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Published on: September 13, 2018

Lassa Virus Treatment Options.

Frederick Hansen¹, Michael A Jarvis², Heinz Feldmann¹

¹Laboratory of Virology, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Hamilton, MT 59840, USA.

|April 30, 2021

Summary

This summary is machine-generated.

Lassa fever remains a significant threat in West Africa, with no approved treatments or vaccines available. Promising therapeutics like favipiravir and monoclonal antibodies show potential in animal models, necessitating clinical trials for Lassa fever treatment.

Keywords:

LASV Lassa animal model antibody antiviral therapeutic

More Related Videos

Standard Operating Procedure for Lyssavirus Surveillance of the Bat Population in Taiwan

Standard Operating Procedure for Lyssavirus Surveillance of the Bat Population in Taiwan

Published on: August 27, 2019

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

Related Experiment Videos

Last Updated: Nov 7, 2025

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Arbovirus Infections As Screening Tools for the Identification of Viral Immunomodulators and Host Antiviral Factors

Published on: September 13, 2018

Standard Operating Procedure for Lyssavirus Surveillance of the Bat Population in Taiwan

Standard Operating Procedure for Lyssavirus Surveillance of the Bat Population in Taiwan

Published on: August 27, 2019

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

A Murine Model of Dengue Virus-induced Acute Viral Encephalitis-like Disease

Published on: April 28, 2019

Area of Science:

Medical Research
Infectious Diseases
Tropical Medicine

Background:

Lassa fever causes 5,000-10,000 deaths annually in West Africa.
Global spread poses public health challenges.
No approved vaccines or treatments exist despite Lassa virus discovery in 1969.

Purpose of the Study:

To review current therapeutics in development for Lassa fever.
To focus on treatments evaluated in human or animal models.
To highlight the need for clinical progression of promising therapies.

Main Methods:

Review of existing literature on Lassa fever therapeutics.
Analysis of preclinical data from animal models (rodents, non-human primates).
Assessment of treatments with potential for clinical application.

Main Results:

Several therapeutics, including favipiravir and a monoclonal antibody cocktail, demonstrated efficacy in preclinical models.
These treatments show promise for Lassa fever treatment in clinical settings.
The development pipeline includes antivirals and antibody-based therapies.

Conclusions:

Favipiravir and monoclonal antibody cocktails are promising preclinical treatments for Lassa fever.
Advancing these Lassa fever therapeutics into clinical trials is crucial.
Addressing this neglected tropical disease requires continued research and development.